Olympus Inks Distro Deal with Endocision

Olympus has begun an exclusive global distribution agreement with Endocision for a portable, single-use flexible cryocatheter system.

Olympus will be the exclusive global distributor of the Endocision platform, which supports a range of diagnostic and therapeutic bronchoscopic procedures. The duo expects to begin commercial launch in the U.S., Canada, and Europe early next year.

The portable system operates without an electrical source or large CO₂ tanks, enabling cryobiopsy and cryoextraction across hospital settings, including bronchoscopy suites, ICUs, operating rooms, and emergency departments. Applications include tissue acquisition, foreign-body and clot removal, tumor debulking, and airway recanalization.  Studies suggest cryobiopsy can provide larger specimens with less crush artifact than conventional forceps biopsy.

The agreement will expand Olympus’ respiratory portfolio, including endobronchial ultrasound (EBUS) for lung and lymph node visualization and biopsy.

Comments from Olympus and Endocision execs

Seiji Kuramoto, executive officer and Surgical and Interventional Solutions division head, Olympus: “This agreement with Endocision highlights Olympus’ commitment to strengthening our respiratory solutions that range from peripheral bronchoscopy and radial EBUS to single-use bronchoscopes that provide the right scope in the right situation. Our collaboration brings together Olympus’ expertise in ultrasound technology and Endocision’s innovative approach to cryotechnology to help support better patient outcomes.”

Dr. Moishe Liberman, president and chief medical officer, Endocision: “We’re excited to introduce the next generation of cryocatheter systems and partner with Olympus to help advance the field of interventional pulmonology and interventional thoracic endoscopy. Endocision Cryocatheter System is designed to support a wide range of bronchoscopic applications, from tissue acquisition to therapeutic airway intervention, while also making cytotechnology accessible across multiple clinical settings.”